Unknown PHASE4 INTERVENTIONAL 2-arm NCT05033769

Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)

AIRE - Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer - a Prospectively Randomized Phase IV Study

Sponsor: Eisai GmbH

Conditions Breast Cancer Female Breast Cancer Metastatic Neoplasm, Breast

Interventions Eribulin Injection [Halaven] Paclitaxel injection

Updated 5 times since 2021 Last updated: Apr 14, 2023 Started: Mar 11, 2021 Primary completion: Jul 1, 2023 Completion: Sep 15, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Breast Cancer Female and Breast Cancer Metastatic and is currently ongoing. Eisai GmbH leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Recruiting → Unknown
May 2023 — Jul 2024 [monthly]

Recruiting PHASE4
Jul 2022 — May 2023 [monthly]

Recruiting PHASE4
Oct 2021 — Jul 2022 [monthly]

Recruiting PHASE4

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai GmbH
Institut fuer Frauengesundheit

Data source: Institut fuer Frauengesundheit

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Erlangen, Germany
• Tübingen, Germany